Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 USD | -0.76% | -2.26% | -34.01% |
03-12 | Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-12 | North American Morning Briefing : Inflation Data -2- | DJ |
Sales 2024 * | 7M 9.55M | Sales 2025 * | 10.8M 14.74M | Capitalization | 62.74M 85.61M |
---|---|---|---|---|---|
Net income 2024 * | -74M -101M | Net income 2025 * | -80M -109M | EV / Sales 2024 * | 8.96 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.81 x |
P/E ratio 2024 * |
-0.84
x | P/E ratio 2025 * |
-0.86
x | Employees | 43 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93% |
1 day | -0.76% | ||
1 week | -2.26% | ||
Current month | -8.45% | ||
1 month | -8.45% | ||
3 months | -2.99% | ||
6 months | -64.48% | ||
Current year | -34.01% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Manfredi
FOU | Founder | 53 | 16-01-31 |
Jotin Marango
DFI | Director of Finance/CFO | 45 | 22-04-24 |
Caroline Germa
CTO | Chief Tech/Sci/R&D Officer | 52 | 02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 16-02-29 | |
David Bonita
BRD | Director/Board Member | 48 | - |
Director/Board Member | 55 | 20-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.3 | -0.76% | 122,141 |
24-04-25 | 1.31 | +1.55% | 138,461 |
24-04-24 | 1.29 | -4.44% | 154,017 |
24-04-23 | 1.35 | +3.85% | 263,930 |
24-04-22 | 1.3 | -2.26% | 239,341 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.01% | 62.74M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IKNA Stock